51632-12-3

Usage

Nitrile compound

A chemical compound containing a cyano group (C≡N) This indicates the presence of a triple bond between carbon and nitrogen atoms.

2-(4-bromo-phenyl) group

A phenyl ring (a six-membered carbon ring with alternating single and double bonds) with a bromine atom attached to the fourth carbon position This group is responsible for the compound's potent biological activity and potential applications in pharmaceuticals and agrochemicals.

Organic synthesis and pharmaceutical research

Commonly used as a building block for the preparation of various biologically active compounds This highlights the compound's importance in creating new and potentially useful substances in the fields of medicine and chemistry.

Potent biological activity

Known for its strong effects on biological systems This property makes the compound valuable in the development of pharmaceuticals and agrochemicals.

Valuable intermediate

Acts as an important step in the production of various compounds This indicates the compound's role in chemical reactions and synthesis processes.

Potential application as a herbicide or pesticide

Studied for its ability to control weeds and pests due to its structural properties This suggests the compound's possible use in agriculture and pest control.

Upstream product

• 75-30-9 2-iodo-propane 
• 16532-79-9 4-Bromophenylacetonitrile 
• 75-26-3 isopropyl bromide 

Downstream Products

• 1360552-02-8 2-[4-(5-methoxypyridin-3-yl)-phenyl]-2,3-dimethylbutyronitrile 
• 1382486-28-3 2-[4-(5-methoxypyridin-3-yl)phenyl]-2,3-dimethylbutyric acid 
• 1360551-17-2 5-(4-{1-[5-(2-methoxy-ethoxymethyl)-[1,2,4]oxadiazol-3-yl]-1,2-dimethyl-propyl}-phenyl)-pyrimidin-2-ylamine 
• 1360552-01-7 2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutyronitrile 
• 1360549-35-4 5-(4-{(R)-1,2-dimethyl-1-[5-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]propyl}phenyl)pyrimidin-2-ylamine 
• 1360549-36-5 5-(4-{(S)-1,2-dimethyl-1-[5-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]propyl}phenyl)pyrimidin-2-ylamine 
• 1360549-05-8 5-(4-{1,2-dimethyl-1-[5-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]propyl}phenyl)pyrimidin-2-ylamine 
• 1360549-56-9 5-(4-{2-methyl-1-[5-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]propyl}phenyl)pyrimidin-2-ylamine 
• 1360552-05-1 2-[4-(2-aminopyrimidin-5-yl)phenyl]-N-hydroxy-3-methylbutyramidine 
• 1360552-12-0 3-[2-(4-bromophenyl)-3-methylbutan-2-yl]-5-cyclopropyl-1,2,4-oxadiazole 
• 1360553-46-3 2-[4-(2-aminopyrimidin-5-yl)phenyl]-N-hydroxy-2,3-dimethyl butanimidamide 
• 1360551-97-8 2-[4-(2-aminopyrimidin-5-yl)phenyl]-2,3-dimethylbutyronitrile 
• 1360551-93-4 2-(4-bromo-phenyl)-N-hydroxy-2,3-dimethylbutyramidine 
• 1360549-77-4 3-{1-[4-(2-aminopyrimidin-5-yl)phenyl]-1,2-dimethylpropyl}-[1,2,4]oxadiazol-5-ol 

Relevant academic research and scientific papers

Enantioselective Rhodium-Catalyzed Allylic Alkylation of Prochiral α,α-Disubstituted Aldehyde Enolates for the Construction of Acyclic Quaternary Stereogenic Centers

A highly enantioselective rhodium-catalyzed allylic alkylation of prochiral α,α-disubstituted aldehyde enolates with allyl benzoate is described. This protocol provides a novel approach for the synthesis of acyclic quaternary carbon stereogenic centers and it represents the first example of the direct enantioselective alkylation of an aldehyde enolate per se. The versatility of the α-quaternary aldehyde products is demonstrated through their conversion to a variety of useful motifs applicable to target-directed synthesis. Finally, mechanistic studies indicate that high levels of asymmetric induction are achieved from a mixture of prochiral (E)- and (Z)-enolates, which provides an exciting development for this type of transformation.

Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: Discovery of 2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]- N, N -dimethyl-acetamide (BI 665915)

The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described. The use of structure-guided drug design techniques provided compounds that demonstrated excellent FLAP binding potency (IC50 4 synthesis in human whole blood (IC50 4 production.

Enantioselective rhodium-catalyzed allylic substitution with a nitrile anion:construction of acyclic quaternary carbon stereogenic centers

A direct and highly enantioselective rhodium-catalyzed allylic alkylation of allyl benzoate with α-substituted benzyl nitrile pronucleophiles is described. This simple protocol provides a new approach toward the synthesis of acyclic quaternary carbon stereogenic centers and provides the first example of the direct asymmetric alkylation of a nitrile anion. The synthetic utility of the nitrile products is amply demonstrated through conversion to various functional groups and the synthesis of a bioactive aryl piperazine in an expeditious four-step sequence.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.